A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

Summary

This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.

Timeline

Start

2021-06-15

Primary completion

2022-01-31

Completion

2023-11-01

Drugs

Indications